Best-Value Biological Medicine: Ustekinumab

The HSE-Medicines Management Programme (MMP) is undertaking a formal consultation phase as part of the process for the identification of best-value biological (BVB) medicines for ustekinumab.

The MMP roadmap for the prescribing of best-value biological (BVB) medicines in the Irish healthcare setting outlines the criteria that will be considered by the MMP in identifying the BVB medicines for ustekinumab.

Submissions are invited from all relevant stakeholders, and should be emailed to mmp@hse.ie by 1pm on Wednesday 22 January 2025.